Patrick G. Johnston

Patrick G. Johnston's AcademicInfluence.com Rankings

Patrick G. Johnston

Philosophy

#7720

World Rank

#10971

Historical Rank

Logic

#4759

World Rank

#6087

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Patrick G. Johnston's Degrees

PhD Medicine Queen's University Belfast
Masters Medicine Queen's University Belfast

Why Is Patrick G. Johnston Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Patrick G. Johnston was a Northern Irish physician and a leading expert in cancer research. He was a professor of oncology at Queen's University Belfast, where he served as vice-chancellor and president from 1 March 2014, until his death.

(See a Problem?)

Patrick G. Johnston's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

5-Fluorouracil: mechanisms of action and clinical strategies (2003) (4139)
Cancer drug resistance: an evolving paradigm (2013) (3466)
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. (1995) (702)
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. (1994) (437)
The role of BRCA1 in the cellular response to chemotherapy. (2004) (423)
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. (2003) (414)
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. (2003) (313)
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy (2014) (293)
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. (2002) (268)
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. (1992) (239)
HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells (2007) (223)
Nonapical and Cytoplasmic Expression of Interleukin-8, CXCR1, and CXCR2 Correlates with Cell Proliferation and Microvessel Density in Prostate Cancer (2005) (218)
Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan (2004) (216)
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death (2006) (208)
BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy (2007) (208)
CD44 Potentiates the Adherence of Metastatic Prostate and Breast Cancer Cells to Bone Marrow Endothelial Cells (2004) (191)
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. (2002) (179)
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. (2011) (171)
Expansion of the Ki‐67 proliferative compartment correlates with degree of Dysplasia in Barrett's esophagus (1995) (171)
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. (2006) (168)
Anti-apoptotic mechanisms of drug resistance in cancer. (2009) (166)
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents (2001) (165)
BRCA1, a potential predictive biomarker in the treatment of breast cancer. (2007) (164)
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients (2000) (164)
Chemoresistance in solid tumours. (2006) (162)
p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. (1998) (157)
Thymidylate synthase and drug resistance. (1995) (147)
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. (2007) (143)
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP (2005) (142)
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. (2008) (141)
EPO's Alter Ego: Erythropoietin Has Multiple Actions (2002) (140)
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. (2003) (138)
Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer (2016) (136)
Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. (2000) (133)
Capecitabine: a novel agent for the treatment of solid tumors (2001) (128)
Implementing prognostic and predictive biomarkers in CRC clinical trials (2011) (126)
Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. (2014) (124)
Prognostic importance of thymidylate synthase expression in early breast cancer. (1997) (123)
Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. (1991) (121)
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial (2006) (120)
BRCA1: mechanisms of inactivation and implications for management of patients (2002) (119)
Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-κB Transcription and Evasion of Apoptosis (2008) (118)
Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells (2007) (118)
c-FLIP: a key regulator of colorectal cancer cell death. (2007) (114)
The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. (2002) (110)
Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. (2000) (110)
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. (1998) (107)
Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer (1999) (106)
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. (2006) (106)
Immunohistochemical analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. (1989) (103)
Resistance mechanisms to cancer chemotherapy. (2008) (102)
AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer (2013) (102)
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells (2006) (101)
Erythropoietin Receptor Expression in Non‐Small Cell Lung Carcinoma: A Question of Antibody Specificity (2007) (99)
Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer (2014) (98)
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer (2015) (98)
Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. (2000) (98)
Altered expression of the septin gene, SEPT9, in ovarian neoplasia (2003) (96)
STAT1: a modulator of chemotherapy-induced apoptosis. (2004) (94)
The clinical significance of cathepsin S expression in human astrocytomas. (2003) (93)
The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. (2003) (93)
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. (2003) (91)
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges (2017) (91)
BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. (2005) (90)
Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer (2010) (88)
Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells (2008) (88)
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. (2014) (85)
Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer (2014) (82)
Cathepsin S expression: An independent prognostic factor in glioblastoma tumours—a pilot study (2006) (81)
Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways (2011) (78)
RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin (2008) (76)
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. (1997) (74)
The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue (2011) (72)
Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer (2010) (72)
Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation (2008) (72)
Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. (1999) (72)
Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. (1995) (69)
Osteopontin as a target for cancer therapy. (2008) (68)
BRCA1 Regulates the Interferon γ-mediated Apoptotic Response* (2002) (67)
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. (2005) (67)
The emerging role of CD44 in regulating skeletal micrometastasis. (2006) (67)
T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells (2010) (67)
Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification (2017) (67)
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. (2001) (65)
p53 mutation does not affect prognosis in ovarian epithelial malignancies (2001) (65)
Role of genomic markers in colorectal cancer treatment. (2005) (64)
Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer (1999) (63)
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. (1999) (63)
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study (2011) (62)
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. (2007) (62)
Cancer-Related Anemia: Biological Findings, Clinical Implications and Impact on Quality of Life (2005) (60)
Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy (2009) (60)
Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. (1996) (59)
The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-γ-mediated apoptosis (2005) (58)
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). (2002) (57)
Cancer fatigue: the way forward. (2003) (56)
Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. (2011) (56)
The Roles of Thymidylate Synthase and p53 in Regulating Fas-Mediated Apoptosis in Response to Antimetabolites (2004) (56)
HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL (2015) (54)
Immunohistochemical determination of thymidylate synthase in colorectal cancer--methodological studies. (1997) (53)
Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer (2012) (51)
BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3 (2004) (51)
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma (2001) (50)
Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells (2009) (49)
The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells (2007) (48)
Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail‐induced epithelial–mesenchymal transition (2011) (47)
Molecular and biochemical markers in colorectal cancer. (2002) (47)
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges (2018) (45)
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells (2007) (45)
BRCA1 regulates the interferon gamma-mediated apoptotic response. (2002) (44)
The European Cancer Patient’s Bill of Rights, update and implementation 2016 (2016) (44)
Epidermal growth factor up‐regulates CD44‐dependent astrocytoma invasion in vitro (2000) (44)
The role of LEF/TCF factors in neoplastic transformation. (2008) (44)
BCL-2 system analysis identifies high-risk colorectal cancer patients (2016) (43)
Prognostic and therapeutic relevance of c‐FLIP in acute myeloid leukaemia (2013) (43)
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). (2016) (43)
Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. (2011) (43)
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. (2012) (42)
Thymidylate Synthase Expression in Stage II and III Colon Cancer: A Retrospective Review (2001) (41)
The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. (1994) (41)
A catalyst for change: the European cancer Patient's Bill of Rights. (2014) (41)
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. (2008) (39)
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. (1998) (39)
Synergistic interaction between paclitaxel and 8-chloro-adenosine 3',5'-monophosphate in human ovarian carcinoma cell lines. (1999) (38)
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer (2016) (38)
Identification of a protein factor secreted by 3T3-L1 preadipocytes inhibitory for the human MCF-7 breast cancer cell line. (1992) (38)
Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity (2014) (37)
Prognostic value of c‐erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer (2000) (37)
Stage II colorectal cancer: to treat or not to treat. (2005) (37)
The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. (1996) (36)
Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. (2014) (36)
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy (2016) (36)
Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy (2018) (35)
Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients (2005) (35)
The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. (2011) (35)
Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. (1993) (32)
Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis. (2009) (32)
RanGTPase: a candidate for Myc-mediated cancer progression. (2013) (32)
Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer (2008) (31)
Calbindin 2 (CALB2) Regulates 5-Fluorouracil Sensitivity in Colorectal Cancer by Modulating the Intrinsic Apoptotic Pathway (2011) (31)
A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer (2011) (31)
Thymidylate Synthase Expression in Patients with Colorectal Carcinoma Using a Polyclonal Thymidylate Synthase Antibody in Comparison to the TS 106 Monoclonal Antibody (2000) (30)
New Concepts for the Development and Use of Antifolates (1996) (30)
BRCA 1 Functions as a Differential Modulator of Chemotherapy-induced Apoptosis 1 (2003) (29)
Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. (1995) (28)
A Bill of Rights for patients with cancer in Europe. (2014) (28)
Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action. (2016) (27)
Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. (2007) (27)
Detection of cathepsin S cysteine protease in human brain tumour microdialysates in vivo (2007) (26)
Prognostic markers of local relapse in rectal cancer: are we any further forward? (2006) (24)
Predicting the outcome of chemotherapy for colorectal cancer. (2006) (24)
Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era. (2014) (23)
Constitutive and Treatment-Induced CXCL8-Signalling Selectively Modulates the Efficacy of Anti-Metabolite Therapeutics in Metastatic Prostate Cancer (2012) (23)
Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression (2010) (23)
Immunological quantitation of thymidylate synthase‐FdUMP‐5,10‐methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106 (1993) (23)
FLIP: A Targetable Mediator of Resistance to Radiation in Non–Small Cell Lung Cancer (2016) (22)
Generation of a non-small cell lung cancer transcriptome microarray (2008) (22)
Molecular mechanisms of drug resistance in acute myeloid leukaemia (2007) (22)
A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array. (2006) (22)
Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer (2016) (21)
Interaction between Transcription Factor, Basal Transcription Factor 3, and the NH2-Terminal Domain of Human Estrogen Receptor α (2007) (20)
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer (2016) (20)
Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models (2008) (20)
5-Fluorouracil: identification of novel downstream mediators of tumour response. (2004) (19)
Synthesis and in vitro and in vivo evaluation of a series of dihydroisocoumarin derivatives conjugated with fatty acids, alcohols, and amines as potential anticancer agents. (2009) (19)
The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers (2015) (18)
Prostate-derived factor—a novel inhibitor of drug-induced cell death in colon cancer cells (2009) (18)
Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer (2012) (18)
The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. (1995) (18)
Clinical significance of prognostic and predictive markers in colorectal cancer (2002) (17)
Determinants of trimetrexate lethality in human colon cancer cells. (1994) (17)
Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells. (1997) (17)
Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. (2000) (17)
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. (1999) (16)
Genomic markers for decision making: what is preventing us from using markers? (2010) (16)
Dynamical Systems Analysis of Mitochondrial BAK Activation Kinetics Predicts Resistance to BH3 Domains (2008) (16)
Quantitation of thymidylate synthase in human tumors using an ultrasensitive enzyme-linked immunoassay. (1993) (16)
Genomic profiling of cancer: what next? (2005) (16)
The pseudo-caspase FLIP(L) regulates cell fate following p53 activation (2020) (15)
In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide (2010) (15)
The role of interferon-α as a modulator of fluorouracil and leucovorin (1995) (14)
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer (2018) (14)
Paraffin-embedded tissue as a source of RNA for gene expression analysis in oral malignancy. (2008) (14)
The biology of growth regulation in normal and malignant breast epithelium: from bench to clinic. (1995) (13)
Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. (2005) (13)
Fluorouracil: active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels. (1995) (13)
Predictive role of thymidylate synthase (TS) and p53 primary tumor expression in advanced colorectal cancer (1997) (12)
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer‐related cells (2010) (11)
Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines. (2000) (11)
Implication of CDK inhibitors p21 and p27 in the differentiation of HL-60 cells. (2004) (11)
Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites. (1993) (11)
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. (2002) (10)
A novel bacterial vector system for monitoring protein-protein interactions in the cAMP-dependent protein kinase complex. (1997) (10)
Predictive markers for colorectal cancer: current status and future prospects. (2003) (10)
Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan. (1995) (10)
The Colorectal Cancer Coalition: reflections on the future. (2006) (10)
5-Fluorouracil: Molecular mechanisms of cell death (2007) (10)
Cancer mortality in Ireland, 1926-1995. (2003) (9)
The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis (2005) (9)
EphA 2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer (2015) (9)
America's cancer care crisis—is Europe any better? (2013) (8)
Epitope mapping of a series of human thymidylate synthase monoclonal antibodies. (1998) (8)
Colorectal cancer biology: clinical implications. (1995) (8)
Prognostic Value of p53, Glutathione S -Transferase p , and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer 1 (1999) (8)
A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence. (2016) (8)
Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells (2009) (8)
The Colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information (2010) (7)
Abstract 924: Upregulation of the MET transcript is consistently associated with invasion and tumor budding in colorectal cancer (2016) (7)
Of what value genomics in colorectal cancer? Opportunities and challenges. (2004) (7)
The NCI-Ireland consortium: a unique international partnership in cancer care. (2001) (7)
A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. (1999) (7)
A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer (2013) (7)
Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells (2012) (7)
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer (2020) (7)
Desmosomal plaque proteins are preserved in all grades of breast cancer. An immunohistochemical study utilizing monoclonal antibodies to desmoplakin. (1988) (7)
Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581. (2014) (7)
The EU: what's best for UK cancer research and patients? (2016) (6)
STAT1 (2004) (6)
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer (2017) (6)
Advances in Brief Isolation and Mapping of a Human Septin Gene to a Region on Chromosome 17 q , Commonly Deleted in Sporadic Epithelial Ovarian Tumors 1 (2000) (5)
The Approval of Teysuno™/S-1 by the European Medicines Agency: A Potentially Important Advance for Gastric Cancer Patients (2011) (5)
Personalized medicine: does the molecular suit fit? (2013) (5)
Axl Expression is a Poor Prognostic Marker and Regulates Tumour Cell Invasion and Migration in Colorectal Cancer (2012) (5)
A molecular basis for Estrogen Receptor- α deficiency in BRCA1-linked breast cancer (2019) (5)
Recent advances in the biology of colorectal cancer. (1996) (4)
77 – Colorectal Cancer (2014) (4)
Microfluorometric size measurements of human and phage DNA correlate with the degree of in vitro cisplatin treatment. (1991) (4)
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer (2012) (3)
A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. (2019) (3)
European Perspectives: A Dialogue with the European Oncology Community (2012) (3)
Elevation of true creatine kinase-MB in a patient with small-cell lung cancer. (1988) (3)
Immunohistochemical analysis of breast cancer oestrogen receptor status and its correlation with oestrogen receptor biochemical assay (1988) (3)
CD44 Expression on prostate cancer cells correlates with adhesion to bone marrow endothelial cells. (2003) (3)
Fazarabine: A Report of Response in a Patient with Multiply Relapsed Embryonal Cell Carcinoma (1993) (3)
83 Investigation of Post-translational Modifications of c-FLIP (2012) (3)
The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF-mutant colorectal cancer cell lines. (2014) (3)
Delivering a research‐enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program (2015) (3)
Pharmacodynamic Measurements and Predictors of Response to Thymidylate Synthase Inhibitors (1999) (2)
Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer. (2013) (2)
Interleukin-8/CXCR2 signaling plays an important role in conferring resistance of prostate cancer cells to chemotherapy (2007) (2)
Genetic testing for BRCA1 mutation in the UK (2003) (2)
Cell cycle redistribution by fluorodeoxyuridine (fdurd) as a mechanism of fluoropyrmiidine radiosensttization. Supported by an ASTRO Research Fellowship (1993) (2)
The high tide of cancer research in Europe. (2011) (2)
The role of interferon-alpha as a modulator of fluorouracil and leucovorin. (1995) (2)
The potential consequences for cancer care and cancer research of Brexit (2017) (2)
Machine vision based stochastic analysis of cancer cell mitochondrial dysfunction induced by a BH3 domain (2008) (2)
Predictive and prognostic markers in colorectal cancer. (2007) (1)
Ephrins/eph as novel synthetic lethal targets in Kras-mutant colorectal cancer. (2011) (1)
The role of molecular markers in the adjuvant treatment of colorectal cancer (2005) (1)
Human Cell Culture Volume II (2000) (1)
A preoperative clinical staging and metabolic imaging model to predict prognosis in early-stage esophageal adenocarcinoma. (2014) (1)
Therapeutics , Targets , and Chemical Biology Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM 17 (2011) (1)
Molecular profiling from FFPE tissue: Stratification of the Stage II colorectal cancer population (2007) (1)
Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response. (2011) (1)
Preclinical Development A Systems Biology Approach Identi fi es SART 1 as a Novel Determinant of Both 5-Fluorouracil and SN 38 Drug Resistance in Colorectal Cancer (2011) (1)
Therapeutic Targeting of Apoptosis in Cancer (2008) (1)
Transient reversal of bone marrow aplasia associated with lymphocyte depleted hodgkin's disease after combination chemotherapy (1991) (1)
45 POSTER Focal adhesion kinase is a key signalling intermediate in interleukin-8 promoted chemotaxis and adhesion of prostate cancer cells to bone marrow endothelium (2006) (1)
The Role of the c-MET/HGF Signalling Axis as a Critical Regulator of Invasion and Migration in Colorectal Cancer (2014) (1)
Molecular Classification of the invasive front in colorectal cancer (2015) (1)
Abstract 4018: The role of c-MET/HGF signaling as a critical mediator of an invasive and resistant phenotype in colorectal cancer (2015) (1)
Clinical correlation of tumor endocrine markers in lung cancer. (1989) (1)
BRCA1 as a predictive marker of survival in sporadic ovarian cancer (2007) (1)
Cancer-cell intrinsic gene expression signatures minimise the confounding effects of intratumoural heterogeneity in colorectal cancer patient classification (2017) (1)
89 The HDAC Inhibitor Vorinostat Down-regulates c-FLIP and Sensitizes Human Non-small Cell Lung Carcinoma Cell Lines to Ionising Radiation (2012) (1)
Abstract 2079: EpHA2 is an essential driver of invasion and a novel target in KRAS mutant colorectal cancer (2014) (1)
Expert opinion: future frontiers and challenges in cancer medicine. (2012) (1)
Medicine at the fringes. (1993) (0)
Title: Value-based Medicine - a UK and European Perspective (2012) (0)
The interaction between Src-family kinase inhibition and chemotherapy in colorectal cancer cell lines. (2007) (0)
Breast cancer: precancerous lesions (2006) (0)
The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC). (2014) (0)
Analysis of proteasomal subunit expression reveals Rpt4 as a prognostic marker in colorectal cancer (2015) (0)
873 Acute STAT3 Activation in Colorectal Cancer Cells Following HDAC Inhibitor Treatment Results in Apoptosis Resistance (2012) (0)
Abstract 704: RALB GTPase: A critical regulator of DR5 cell surface expression and TRAIL sensitivity inRASmutant colorectal cancer (2019) (0)
BRCA1 mediated G2/M cell cycle arrest in response to taxol. (2000) (0)
Abstract LB-037: Development and preclinical assessment of a first-in-class small molecule inhibitor of the major cell death regulator protein FLIP (2015) (0)
Abstract C177: Src and ADAM17‐mediated shedding of heregulin is a mechanism of acute resistance to chemotherapy in gastro‐oesophageal cancer cells (2009) (0)
Modelling chemotherapeutic treatments of colorectal cancer. (2005) (0)
Targeting the epidermal growth factor receptor in conjunction with Oxaliplatin (2004) (0)
Abstract B243: Kras mutation status as biomarker for response to TRAIL treatment in colorectal cancer (2009) (0)
Prognostic and predictive markers in colorectal cancer - The role of new genomic technologies (2007) (0)
8034 INVITED Future directions in prevention and early detection of colon cancer (2007) (0)
The role of STAT3 and c-FLIP as acute resistance mechanisms to MEK inhibition in BRAF mutant colorectal cancer (2014) (0)
CD44 signalling increases cathepsin K and MT1-MMP (2007) (0)
Enzyme-Catalyzed Antimicrobial Activation (2002) (0)
The role of ADAM-17 in chemotherapy-induced EGFR activation (2007) (0)
) Origin of the content of the completed Lung Cancer DSA, showing that the majority of the array con (2011) (0)
Pharmacogenomics of Colorectal Cancer (2006) (0)
The Management of Colorectal Cancer — The Integration of Biological Agents and Identification of New Targets (2007) (0)
Prognostic significance of glycoprotein pMQ1 in breast cancer (2006) (0)
Abstract C12: Preclinical characterization of a novel FLIP‐targeted antisense phosphorothioate oligonucleotide (2009) (0)
492 POSTER Role of human epidermal receptor targeted therapies in chemo-sensitization of oesophageal adenocarcinoma cells (2008) (0)
Biomarker identification and clinical validation (2016) (0)
Abstract 1153: The development and utilization of a novel DNA microarray platform for biomarker and target identification in advanced prostate cancer (2010) (0)
Identification of Reprogramming of the Kinome following Vemurafenib Treatment in BRAF mutant Colorectal Cancer Cells (2012) (0)
c-FLIP maintains colorectal cancer cell survival (2007) (0)
CD44 Initiates integrin-promoted cortactin and paxillin signaling to promote adhesion of metastatic breast and prostate cancer cells to bone marrow endothelium (2009) (0)
Investigating the role of EGFR and HER-2 in modulating death ligand-induced apoptosis (2006) (0)
HUMAN THYMIDYLATE SYNTHASE MONOCLONAL ANTIBODIES AND HYBRIDOMAS PRODUCING THE SAME ANTI- HUMANE THYMIDYLAT- SYNTHASE MONOKLONALE ANTIKÖRPER UND HYBRIDOMAZELLEN ZU DEREN HERSTELLUNG ANTICORPS MONOCLONAUX CONTRE LA THYMIDYLATE SYNTHASE HUMAINE ET HYBRIDOMES PRODUISANT CES ANTICORPS (0)
89 INVITED Molecular markers and patient selection in colorectal cancer (2007) (0)
Title: Health Technology Assessment in Cancer: Driving Efficiency and Efficacy, but at What Cost? (2015) (0)
Invited Papers (2002) (0)
Predicting response to irinotecan/5-fluorouracil (5-FU) chemotherapy for advanced colorectal cancer based on gene expression in primary tumour. (2009) (0)
Transcriptional regulation of thymidylate synthase as a mechanism of resistance to 5-fluorouracil and tomudex. (2000) (0)
360 The therapeutic relevance of the molecular biology of colorectal cancer (2003) (0)
Deterministic Modelling of BAK Activation Kinetics (2009) (0)
43 POSTER CD44 regulates the expression of the cysteine protease Cathepsin K: implications for bone metastasis of breast cancer (2006) (0)
160 Ku70 Acetylation as a Determinant of Chemosensitivity in Colorectal Cancer (2012) (0)
Unified model incorporating both b1 driven and spontaneous activation of B. (2013) (0)
Interleukin-8 signalling contributes to chemotherapy resistance in colorectal cancer cells (2008) (0)
BRCA1 mediated cell apoptosis in response to taxol (2002) (0)
1 BACKGROUND AND IMPLEMENTATION PLAN FOR THE EUROPEAN CANCER PATIENT’S BILL OF RIGHTS, 2016 (ARCHIVE) ECC Members (2017) (0)
The Promise of Biological Markers as Prognostic Determinants in Colorectal Cancer (2005) (0)
EphA2 is an essential driver of invasion downstream of the KRAS signalling cascade in colorectal cancer. (2014) (0)
NCI All Ireland Cancer Agreement: An Auspicious Beginning (2000) (0)
Inhibition of FGFR4 increases oxaliplatin and 5-fluorouracil sensitivity in Kras wild-type and mutant colorectal cancer cells. (2011) (0)
c-FLIP inhibits Fas-mediated apoptosis in response to chemotherapy. (2004) (0)
Identification of predictive markers of response to 5-Fluorouracil and oxaliplatin in metastatic colorectal cancer (2006) (0)
173 POSTER NFkB is a critical mediator of BRCA1 induced chemoresistance (2006) (0)
Interleukin-8 (IL-8) promotes autocrine growth of prostate cancer cells (2002) (0)
Human Cells and Tissue Localize Human Thymidylate Synthase in the Cytoplasm of Production and Characterization of Monoclonal Antibodies That (2006) (0)
Rational targeting of Inhibitor of Apoptosis Proteins (IAPs)for effective therapy of colorectal cancer (2014) (0)
Irish Society of Gastroenterology — Winter Meeting Held at Freeman Auditorium, Mater Misericordiae Hospital, Dublin on Friday, 20th and Saturday, 21st November, 1987 (1988) (0)
FLIP(L) determines p53 induced life or death (2019) (0)
Abstract 2409: FLIP(L) determines colon cancer cell fate following p53 activation (2020) (0)
Genomic profiling of colorectal cancer. (2009) (0)
FLIP-mediated radio-resistance in NSCLC 2 (2016) (0)
A method for determining whether a tumor cell is invasive and / or metastatic potential, and means tilmodulering of malignant transformation (2007) (0)
Could we decide adjuvant therapy of colon cancer based on microarrays? (2007) (0)
Genomic signature of prognosis for Stage II colorectal cancer from FFPE tissue (2007) (0)
The c-MET-JAK1/2-STAT3 signalling axis is regulated by ADAM17 and is a key mediator of resistance to MEK inhibition in KRAS mutant colorectal cancer (2013) (0)
Selective activation of MAPK pathways promotes the growth of metastatic prostate cancer cells by interleukin-8 (IL-8) (2003) (0)
Identification of 5-FU inducible genes in tumour cell lines by cDNA mircroarray (2002) (0)
The Second Challenge : Embedding Our Redefined Cancer Biology in Cancer Care (2012) (0)
Treatment of Cancer: Pancreatic Cancer. (2014) (0)
Bruce Chabner awarded the Bob Pinedo Prize: a celebration of translational research and patient care excellence. (2007) (0)
Topoisomerase II targeted drugs modulate IFNgamma-regulated gene targets leading to enhanced cell death (2003) (0)
Familial Breast and Ovarian Cancer: Gene therapy for breast and ovarian cancer (2002) (0)
Comparative Genomic Hybridization Analysis of Chromosomal Alterations Induced by the Development of Resistance to Thymidylate Synthase Inhibitors1 (2006) (0)
397 Aurocrine interleukin-8 signalling in prostate cancer cells promotes translation of cyclin D1 (2004) (0)
Gene expression profiling assays as predictors of poor prognosis in stage II colorectal cancer: A meta-analysis (2008) (0)
BRCA1 is a differential mediator of apoptosis. (2003) (0)
Using biologic markers to optimize therapies (2005) (0)
Assessing the stability of clinically relevant prognostic, predictive and subtyping gene expression signatures based on intra-tumoural heterogeneity in colorectal cancer (2016) (0)
Abstract 4324: Axl receptor tyrosine kinase expression regulates tumor cell invasion and migration in colorectal cancer (2012) (0)
BRCA1 Regulates the Interferon (cid:1) -mediated Apoptotic Response* (2002) (0)
A novel role for BRCA1 in mediating the interferon gamma antiproliferative response (2002) (0)
Abstract 4924: Retrospective evaluation of a system model of the BCL2 family of proteins as a predictive and prognostic biomarker for the clinical outcome of stage II-IV colorectal cancer patients (2016) (0)
Inhibition of an intracrine interleukin-8 signalling loop decreases prostate cancer cell proliferation. (2003) (0)
498 POSTER Interleukin-8 signalling contributes to chemotherapy resistance in colorectal cancer cells (2008) (0)
Identification of subtypes in colorectal cancer and their prognostic values. (2009) (0)
Thymidylate S ynthase P rotein E xpression i n P rimary Colorectal C ancer: L ack o f C orrelation W ith O utcome a nd Response t o F luorouracil i n M etastatic D isease S ites (2003) (0)
Reply to L. Casadaban et al. (2017) (0)
Interleukin-8 (IL-8) promotes the growth of metastatic prostate cancer cells (2002) (0)
Advances in Brief Comparative Genomic Hybridization Analysis of Chromosomal Alterations Induced by the Development of Resistance to Thymidylate Synthase Inhibitors 1 (2006) (0)
620 Elevated expression of IL-8 and IL-8 receptors in prostate cancer cells correlates with disease progression and resistance to oxaliplatin (2004) (0)
Abstract B64: The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF mutant colorectal cancer. (2013) (0)
New concepts for the development and use of antifolates. (1996) (0)
Abstract LB-016: Nutlin and oxaliplatin induce p53-dependent addiction to FLIP (2016) (0)

This paper list is powered by the following services:

Other Resources About Patrick G. Johnston

en.wikipedia.org

What Schools Are Affiliated With Patrick G. Johnston?

Patrick G. Johnston is affiliated with the following schools:

Patrick G. Johnston's Academic­Influence.com Rankings